Orris

asthma prophylaxis

Reading File
Finding Sources
Finding Sources
Searching PubMed

"asthma"[MeSH Terms] AND prophylaxis

Searching the Web

asthma prophylaxis medications guidelines 2024 2025

Asthma Prophylaxis

"Prophylaxis" in asthma means the long-term controller therapy used to prevent attacks/exacerbations, as opposed to relievers used to abort an acute attack. The two are pharmacologically distinct.

1. Inhaled corticosteroids (ICS) - first-line controller

The cornerstone of prophylaxis in virtually all asthma severities. Examples: beclometasone, budesonide, fluticasone, ciclesonide.
  • Reduce airway inflammation, mucosal edema, and mucus hypersecretion; decrease exacerbation frequency and mortality.
  • Current GINA guidance (2024-2025 update) explicitly moved away from using a short-acting beta agonist (SABA) alone as reliever in adults/adolescents - everyone with asthma should be on an ICS-containing regimen, because SABA-only use raises exacerbation risk (GINA 2025 report).

2. Leukotriene receptor antagonists (LTRA)

Montelukast, zafirlukast: block leukotriene D4 receptors, reducing bronchoconstriction and inflammation.
  • Per Katzung's Basic and Clinical Pharmacology, these are used for "prophylaxis of asthma, especially in children" and are effective at blocking airway response to exercise and antigen challenge - i.e., useful for exercise-induced bronchospasm (EIB) and allergen-triggered asthma - Katzung's Basic and Clinical Pharmacology, 16th Ed.

3. Mast cell stabilizers

Cromolyn sodium and nedocromil: prevent mast cell degranulation, blocking release of histamine and leukotrienes.
  • Useful as prophylaxis against exacerbations (particularly pre-exercise or pre-allergen exposure) but have no role in treating an acute attack, since they are not bronchodilators - Fishman's Pulmonary Diseases and Disorders.

4. Long-acting beta agonists (LABA)

Salmeterol, formoterol - never used as monotherapy (black box risk of increased asthma death), always combined with an ICS in a single inhaler for maintenance and/or maintenance-and-reliever therapy (MART, using ICS-formoterol).

5. Biologic/monoclonal antibody therapy (severe/allergic asthma)

  • Omalizumab (anti-IgE) - for moderate-severe allergic asthma with elevated IgE.
  • Mepolizumab, reslizumab, benralizumab (anti-IL-5/IL-5R) and dupilumab (anti-IL-4/13) - for eosinophilic/T2-high severe asthma, added when ICS-based therapy fails to control disease.

6. Systemic corticosteroids and steroid-sparing considerations

Chronic or frequent "burst" oral corticosteroid use is sometimes needed in severe disease, but carries major toxicity; patients on chronic prednisone ≥20 mg/day need Pneumocystis prophylaxis and bone health measures (bisphosphonates/calcium/vitamin D) - Harrison's Principles of Internal Medicine, 22nd Ed.

7. Non-pharmacologic prophylaxis

  • Allergen/trigger avoidance (dust mites, pet dander, smoke, occupational irritants).
  • Written asthma action plans and inhaler technique education.
  • Annual influenza vaccination; pneumococcal vaccination where indicated.
  • Treating comorbid allergic rhinitis/GERD which can worsen control.

Current guideline framework (GINA 2024-2025)

GINA now recommends a "two-track" stepwise approach for ages 12+:
  • Track 1 (preferred): low-dose ICS-formoterol used both as daily controller and as-needed reliever (reduces exacerbations vs SABA reliever).
  • Track 2 (alternative): regular ICS or ICS-LABA controller with a separate SABA reliever, used when adherence to Track 1 is expected to be poor. For children ≤5, daily low-dose ICS remains the standard controller, with SABA as needed for symptoms.
I did not find recent systematic reviews/meta-analyses specific to asthma controller prophylaxis in the last 2 years (the PubMed search for "asthma AND prophylaxis" returned only ECMO/ventilator-associated pneumonia antibiotic prophylaxis papers, which are unrelated) - so no contradicting recent evidence to flag against the guideline summary above. The GINA 2025 update and the March 2025 VA/DoD primary care asthma guideline are the most current authoritative sources; if you want, I can pull the detailed step-by-step dosing/inhaler choice tables from either.
This is a shared conversation. Sign in to Orris to start your own chat.